



## Supplementary Materials



**Figure S1.** Flow diagram of patient enrollment.



	Month in 2020									
<b>TP</b>	31	132	46	18	4	6	10	12	23	
<b>TP + FP</b>	31	137	49	18	6	7	12	14	26	
<b>PPV, %</b>	100.0	96.4	93.9	100.0	66.7	85.7	83.3	85.7	88.5	
<b>95% CI, %</b>	(88.8, 100.0)	(91.7, 98.8)	(83.1, 98.7)	(81.5, 100.0)	(22.3, 95.7)	(42.1, 99.6)	(51.6, 97.9)	(57.2, 98.2)	(69.8, 97.6)	

**Figure S2.** PPV of severe COVID-19 against medical chart review by month. A total of 300 patients who met the Pfizer/BioNTech COVID-19 vaccine trial definition of severe COVID-19 illness was selected by random sampling without replacement. Data for November were available only up to November 19, 2020.

**Table S1.** COVID-19 diagnostic measures

Diagnostic measure	Overall (March–November <sup>†</sup> 2020) N = 354,124
<b>PCR</b>	
Patients with ≥1 PCR test, n (%)	335,043 (94.6)
Patients with ≥1 positive test	21,775 (6.5)
Patients without any positive tests	313,268 (93.5)
Patients with ≥1 negative test	323,031 (96.4)
Number of PCR tests per patient, mean ± SD [median]	2.2 ± 1.7 [2.0]
Total number of PCR tests	726,652
Positive, n (%)	42,930 (5.9)
Negative, n (%)	683,722 (94.1)
<b>ICD-10-CM diagnosis code (U07.1)<sup>‡</sup></b>	
Patients with ≥1 ICD-10-CM diagnosis code (U07.1), n (%)	39,576 (11.2)
Number of ICD-10-CM codes per patient, mean ± SD [median]	3.0 ± 5.4 [2.0]

Data are shown as n (%) unless otherwise indicated.

<sup>†</sup>Data for November were available only up to November 19, 2020.

<sup>‡</sup>Defined as “COVID-19, virus identified”, effective April 1, 2020.

Abbreviations: COVID-19, coronavirus disease 2019; ICD-10-CM, International Classification of Diseases 10th Revision, Clinical Modification; PCR, polymerase chain reaction; SD, standard deviation.

**Table S2.** Frequency of severe or critical COVID-19 illness endpoints per WHO definition in patients hospitalized with COVID-19

Endpoint	All patients hospitalized with COVID-19 N = 3,580
<b>Patients meeting WHO definition of severe or critical COVID-19 illness, n (%)</b>	<b>2,822 (78.8)</b>
<b>Patients meeting WHO definition of severe COVID-19 illness<sup>†</sup>, n (%)</b>	<b>2,697 (75.3)</b>
SpO <sub>2</sub> <sup>‡</sup>	
Patients with SpO <sub>2</sub> available	3,578 (99.9)
SpO <sub>2</sub> <90%	1,931 (54.0)
Respiratory frequency <sup>‡</sup>	
Patients with respiratory frequency available	3,573 (99.8)
Respiratory frequency >30 breaths/min	1,626 (45.5)
Signs of severe respiratory distress <sup>¶</sup>	1,705 (47.6)
<b>Patients meeting WHO definition of critical COVID-19 illness<sup>§</sup>, n (%)</b>	<b>1,454 (40.6)</b>
Requiring life-sustaining treatment	994 (27.8)
Vasopressors <sup>¶</sup>	914 (25.5)
Invasive ventilation <sup>#</sup>	738 (20.6)
Noninvasive ventilation <sup>#</sup>	605 (16.9)
Acute respiratory distress syndrome <sup>¶</sup>	1,167 (32.6)
Sepsis <sup>¶</sup>	494 (13.8)
Septic shock <sup>¶</sup>	334 (9.3)

<sup>†</sup>Patients meeting the WHO definition of severe COVID-19 illness had at least one of the listed endpoints during hospitalization with COVID-19.

<sup>‡</sup>If a patient had multiple measurements on the same day, the most severe result was used.

<sup>¶</sup>Identified using diagnosis codes.

<sup>§</sup>Patients meeting the WHO definition of critical COVID-19 illness had at least one of the listed endpoints during hospitalization with COVID-19.

<sup>¶</sup>Identified through string searches of medication names including dopamine, dobutamine, milrinone, levosimendan, epinephrine, norepinephrine, vasopressin, and phenylephrine.

<sup>#</sup>Identified from structured procedure data based on procedure codes and from respiratory therapy-related procedure data curated by Mass General Brigham.

Abbreviations: COVID-19, coronavirus disease 2019; SpO<sub>2</sub>, oxygen saturation; WHO, World Health Organization.

**Table S3.** Validation of severe or critical COVID-19 illness endpoints per WHO definition against medical chart review

Endpoint	PPV <sup>†‡</sup>		
	TP	TP + FP	PPV % (95% CI) <sup>¶</sup>
<b>Patients meeting WHO definition of severe or critical COVID-19 illness</b>	<b>190</b>	<b>244</b>	<b>77.9 (72.1, 82.9)</b>
<b>Patients meeting WHO definition of severe COVID-19 illness<sup>§</sup></b>	<b>186</b>	<b>237</b>	<b>78.5 (72.7, 83.5)</b>
SpO <sub>2</sub> <90% <sup>  </sup>	157	172	91.3 (86.0, 95.0)
Respiratory frequency >30 breaths/min	127	136	93.4 (87.8, 96.9)
Signs of severe respiratory distress <sup>#</sup>	111	149	74.5 (66.7, 81.3)
<b>Patients meeting WHO definition of critical COVID-19 illness<sup>††</sup></b>	<b>108</b>	<b>119</b>	<b>90.8 (84.1, 95.3)</b>
Requiring life-sustaining treatment	79	85	92.9 (85.3, 97.4)
Vasopressors <sup>‡‡</sup>	76	81	93.8 (86.2, 98.0)
Invasive ventilation <sup>¶¶</sup>	64	66	97.0 (89.5, 99.6)
Noninvasive ventilation <sup>¶¶</sup>	48	49	98.0 (89.1, 99.9)
Acute respiratory distress syndrome <sup>#</sup>	95	102	93.1 (86.4, 97.2)
Sepsis <sup>#</sup>	51	52	98.1 (89.7, 100.0)
Septic shock <sup>#</sup>	37	38	97.4 (86.2, 99.9)

<sup>†</sup>Validation was conducted in a subset of the 300 patients who met the WHO definition of severe or critical COVID-19 illness based on codified data.

<sup>‡</sup>PPV was calculated as TP/ (TP + FP), where TP and FP were patients meeting the WHO definition of severe COVID-19 illness by medical chart review and those with the corresponding endpoint determined from codified data, respectively.

<sup>¶</sup>Exact CIs are presented for each validation measure.

<sup>§</sup>Patients who met the WHO definition of severe COVID-19 illness had at least one of the listed endpoints during hospitalization with COVID-19.

<sup>||</sup>Endpoints were identified from clinical sign-related or laboratory data curated by Mass General Brigham.

<sup>#</sup>Identified from structured diagnosis data based on diagnosis codes.

<sup>††</sup>Patients who met the WHO definition of critical COVID-19 illness had at least one of the listed endpoints during hospitalization with COVID-19.

<sup>‡‡</sup>Identified through string searches of medication names including dopamine, epinephrine, norepinephrine, and vasopressin.

<sup>¶¶</sup>Identified from structured procedure data based on procedure codes and from respiratory therapy-related procedure data curated by Mass General Brigham.

Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; FP, false positive; PPV, positive predictive value; SpO<sub>2</sub>, oxygen saturation; TP, true positive; WHO, World Health Organization.

**Table S4.** Validation of non-severe COVID-19 illness in codified data against medical chart review

Endpoint	NPV <sup>†‡</sup>		
	TN	TN + FN	NPV % (95% CI) <sup>¶</sup>
Patients not meeting vaccine trial definition of severe COVID-19 illness <sup>§</sup>	75	100	75.0 (65.3, 83.1)
Patients not meeting WHO definition of severe or critical COVID-19 illness	66	72	91.7 (82.7, 96.9)

<sup>†</sup>NPV was calculated based on a subgroup of 100 patients who did not meet the Pfizer/BioNTech COVID-19 vaccine trial definition of severe COVID-19 illness based on codified data.

<sup>‡</sup>NPV was calculated as  $TN / (TN + FN)$ , where TN and FN were patients who did not meet the definition of severe COVID-19 illness based on chart review and codified data, respectively.

<sup>¶</sup>Exact CIs are presented for each validation measure.

<sup>§</sup>Patients with hospitalizations that were determined to not be COVID-19–related through chart review were categorized as TN.

Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; FN, false negative; NPV, negative predictive value; TN, true negative; WHO, World Health Organization.